HESTERBIO
Hester Biosciences Limited
Each stock's 10,000-path forecast, rendered as light.
Hester Biosciences Limited (HESTERBIO) Stock Analysis & Case Study
Is HESTERBIO a good buy? The data-driven verdict.
Hester Biosciences Limited (HESTERBIO) trades at ₹2,418,on the numbers it mixed signals, a Downstox Snapshot Score of 47/100.
On the numbers, Hester Biosciences Limited (HESTERBIO) mixed signals, a Downstox Snapshot Score of 47/100, weighing premium at 38.7× earnings, ROE of 15.9%, a 51% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
HESTERBIO fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How HESTERBIO ranks against the 2,373 companies in our screener
- HESTERBIO's market cap of 2,057 Cr ranks in the 51st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HESTERBIO's book value of ₹423 ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HESTERBIO's promoter holding of 53.7% ranks in the 39th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HESTERBIO's 3-year profit (PAT) growth of 26.0% ranks in the 65th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HESTERBIO's 3-year revenue growth of 8.0% ranks in the 44th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HESTERBIO's debt-to-equity ratio of 0.54x is lower than 33% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is HESTERBIO overvalued? HESTERBIO P/E vs peers
HESTERBIO trades at 38.7× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
HESTERBIO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of HESTERBIO history (12%/yr drift, 44%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| HESTERBIO 2027 | ₹1,419 | ₹2,453 | ₹4,239 | +1% |
| HESTERBIO 2028 | ₹1,122 | ₹2,488 | ₹5,516 | +3% |
| HESTERBIO 2029 | ₹930 | ₹2,524 | ₹6,850 | +4% |
| HESTERBIO 2030 | ₹803 | ₹2,560 | ₹8,164 | +6% |
| HESTERBIO 2031 | ₹727 | ₹2,597 | ₹9,279 | +7% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability HESTERBIO goes up, or doubles?
The bull case for HESTERBIO
- HESTERBIO's return on equity of 15.9% ranks in the 74th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹6,850.
The bear case & risks
- HESTERBIO's P/E of 38.7x is lower than 35% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹930.
HESTERBIO volatility & expected range, how bumpy is the ride?
Over the last 9.8 years HESTERBIO compounded at 12%/year with annualized volatility of 44%. That volatility implies a 1-year 80% range of ₹1,419-₹4,239, the honest backbone behind any single price target.
HESTERBIO price forecast, the full 60-month probability fan
HESTERBIO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds HESTERBIO hits common targets within the simulated horizon?
Full multi-horizon detail on the HESTERBIO price target & forecast page.
HESTERBIO Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. HESTERBIO scores 6/8, mixed financial health.
HESTERBIO MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy HESTERBIO with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 36.38% | 2.7× |
| Zerodha | 50.00% | 2.0× |
| Groww | 36.53% | 2.7× |
| Dhan | 50.00% | 2.0× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 36.73% | 2.7× |
| Pocketful | 50.00% | 2.0× |
| Anand RathiCHEAPEST | 36.35% | 2.8× |
| Bajaj Broking | 45.00% | 2.2× |
| Share India | 36.49% | 2.7× |
Compare every broker on the HESTERBIO MTF page.
About Hester Biosciences Limited: sector, index & market-cap context
Hester Biosciences Limited (HESTERBIO) is a small-cap NSE-listed company, with a market capitalisation of ₹2,057 Cr. See more stocks on our screener.
How the HESTERBIO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Hester Biosciences Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
HESTERBIO analysis, FAQs
Is Hester Biosciences Limited (HESTERBIO) a good buy?
On the numbers, Hester Biosciences Limited (HESTERBIO) mixed signals, a Downstox Snapshot Score of 47/100, weighing premium at 38.7× earnings, ROE of 15.9%, a 51% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is HESTERBIO overvalued or undervalued?
HESTERBIO trades at 38.7× earnings, premium versus the ~22× long-run Nifty average.
What is the HESTERBIO share price target for 2031?
HESTERBIO's probability-weighted 2031 median target is ₹2,597, with an 80% range of ₹727-₹9,279 (10,000-path Monte-Carlo).
What is the probability HESTERBIO doubles in 5 years?
The modelled probability of HESTERBIO reaching ₹4,836 (2×) within 5 years is 27%.
What is the bull case for HESTERBIO?
HESTERBIO's return on equity of 15.9% ranks in the 74th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in HESTERBIO?
HESTERBIO's P/E of 38.7x is lower than 35% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.